Differential alteration of drug-metabolizing enzyme activities after cyclophosphamide/adriamycin administration in breast cancer patients

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 29, Issue 1, 2007, Pages 27-32

  Elkiran, Tamer ^a,c   Harputluoglu, H ^a   Yasar, U ^b   Babaoglu, M O ^b   Dincel, A K ^b   Altundag, K ^a   Ozisik, Y ^a   Guler, N ^a   Bozkurf, A ^b  

^a Institute of Oncology   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c FIRAT UNIVERSITY   (Turkey)

Author keywords

Adriamycin; Cyclophosphamide; Cytochrome P450; Induction; Inhibition

Indexed keywords

AMLODIPINE; ARYLAMINE ACETYLTRANSFERASE; ATENOLOL; ATORVASTATIN; CAFFEINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; DILTIAZEM; DOXORUBICIN; DRUG METABOLIZING ENZYME; ENALAPRIL; GRANISETRON; INDAPAMIDE; LOSARTAN; ONDANSETRON; PARACETAMOL; SERTRALINE; XANTHINE OXIDASE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NAUSEA AND VOMITING; SINGLE DRUG DOSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARYL HYDROCARBON HYDROXYLASES; ARYLAMINE N-ACETYLTRANSFERASE; BREAST NEOPLASMS; CAFFEINE; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP1A2; DOXORUBICIN; DRUG INTERACTIONS; FEMALE; HUMANS; LOSARTAN; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PROSPECTIVE STUDIES; XANTHINE OXIDASE;

EID: 33947369020     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2007.29.1.1074690     Document Type: Article

References (40)

1. Xie, H., Griskevicius, L., Stahle, L. et al. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Scis 2006, 27: 54-61.
2. Xie, H.J., Yasar, U., Lundgren, S. et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 2003, 3: 53-61.
3. Griskevicius, L., Yasar, U., Sandberg, M. et al. Bioactivation of cyclophosphamide: The role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol 2003, 59: 103-9.
4. Huang, Z., Roy, P., Waxman, D.J. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000, 59: 961-72.
5. Angley, M.T., Sansom, L.N., Stupans, I. Cyclophosphamide administered repeatedly to the male rat and as a single dose to the female rat. Its effects on hepatic and pulmonary P450 and associated enzymes. Xenobiotica 1995, 25: 1051-62.
6. Kraner, J.C., Morgan, E.T., Poet, T.S., Born, S.L., Burnett, V.L., Halpert, J.R. Suppression of rat hepatic microsomal cytochromes P450 by cyclophosphamide is correlated with plasma thyroid hormone levels and displays differential strain sensitivity. J Pharmacol Exp Ther 1996, 276: 258-64.
7. Xie, H., Afsharian, P., Terelius, Y. et al. Cyclophosphamide induces mRNA, protein and enzyme activity of cytochrome P450 in rat. Xenobiotica 2005, 35: 239-51.
8. Chang, T.K., Yu, L., Maurel, P., Waxman, D.J. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997, 57: 1946-54.
9. Gervot, L., Rochat, B., Gautier, J.C. et al. Human CYP2B6: Expression, inducibility and catalytic activities. Pharmacogenetics 1999, 9: 295-306.
10. Lindley, C., Hamilton, G., McCune, J.S. et al. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos 2002, 30: 814-22.
11. Ren, S., Kalhorn, T.F., McDonald, G.B., Anasetti, C., Appelbaum, F.R., Slattery, J.T. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin Pharmacol Ther 1998, 64: 289-301.
12. Hassan, M., Svensson, U.S., Ljungman, P. et al. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br J Clin Pharmacol 1999, 48: 669-77.
13. McGuire, T.R., Gwilt, P., Manouvilov, K. et al. High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation. Int Immunopharmacol 2003, 3: 279-83.
14. Lear, L., Nation, R.L., Stupans, I. Effects of cyclophosphamide and adriamycin on rat hepatic microsomal glucuronidation and lipid peroxidation. Biochem Pharmacol 1992, 44: 747-53.
15. Mungikar, A.M., Gothoskar, B.P. Depression of mouse liver microsomal mixed function oxidase enzymes by adriamycin. Toxicol Lett 1985, 29: 17-23.
16. Mimnaugh, E.G., Trush, M.A., Ginsburg, E., Hirokata, Y., Gram, T.E. The effects of adriamycin in vitro and in vivo on hepatic microsomal drug-metabolizing enzymes: Role of microsomal lipid peroxidation. Toxicol Appl Pharmacol 1981, 61: 313-25.
17. Mimnaugh, E.G., Trush, M.A., Gram, T.E. Stimulation by adriamycin of rat heart and liver microsomal NADPH-dependent lipid peroxidation. Biochem Pharmacol 1981, 30: 2797-804.
18. Marchand, D.J., Renton, K.W. Depression of cytochrome P-450-dependent drug biotransformation by adriamycin. Toxicol Appl Pharmacol 1981, 58: 83-8.
19. Allabi, A.C., Gala, J.L., Horsmans, Y. et al. Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans. Clin Pharmacol Ther 2004, 76: 113-8.
20. Babaoglu, M.O., Yasar, U., Sandberg, M. et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 2004, 60: 337-42.
21. Yasar, U., Tybring, G., Hidestrand, M. et al. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001, 29: 1051-6.
22. Yasar, U., Dahl, M.L., Christensen, M., Eliasson, E. Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. Br J Clin Pharmacol 2002, 54: 183-5.
23. Campbell, M.E., Spielberg, S.P., Kalow, W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987, 42: 157-65.
24. Carrillo, J.A., Christensen, M., Ramos, S.I. et al. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit 2000, 22: 409-17.
25. Gu, L., Gonzalez, F.J., Kalow, W., Tang, B.K. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992, 2: 73-7.
26. Kalow, W., Tang, B.K. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991, 50: 508-19.
27. Kalow, W., Tang, B.K. The use of caffeine for enzyme assays: A critical appraisal. Clin Pharmacol Ther 1993, 53: 503-14.
28. Grant, D.M., Tang, B.K., Kalow, W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984, 17: 459-64.
29. Yasar, U., Forslund-Bergengren, C., Tybring, G. et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002, 71: 89-98.
30. Krul, C., Hageman, G. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998, 709: 27-34.
31. Tang, B.K., Kadar, D., Qian, L., Irian, J., Yip, J., Kalow, W. Caffeine as a metabolic probe: Validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991, 49: 648-57.
32. Streetman, D.S., Bertino, J.S., Jr., Nafziger, A.N. Phenotyping of drug-metabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000, 10: 187-216.
33. Sekino, K., Kubota, T., Okada, Y. et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003, 59: 589-92.
34. Gunes, A., Coskun, U., Boruban, C. et al. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. Basic Clin Pharmacol Toxicol 2006, 98: 197-200.
35. Kortunay, S., Bozkurt, A., Basci, N.E., Brosen, K., Kayaalp, S.O. Dose-dependent inhibition of the CYP2D6 catalyzed oxidation of sparteine by mepyramine in healthy volunteers. Pharmacol Toxicol 2001, 89: 331-4.
36. Kortunay, S., Bozkurt, A., Basci, N.E., Kayaalp, S.O. Effects of terfenadine and diphenhydramine on the CYP2D6 activity in healthy volunteers. Eur J Drug Metab Pharmacokinet 2002, 27: 171-4.
37. Madsen, H., Enggaard, T.P., Hansen, L.L., Klitgaard, N.A., Brosen, K. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clin Pharmacol Ther 2001, 69: 41-7.
38. Transon, C., Leemann, T., Vogt, N., Dayer, P. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin. Clin Pharmacol Ther 1995, 58: 412-7.
39. Lin, J.H., Lu, A.Y. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 2001, 41: 535-67.
40. Niwa, T., Yamamoto, S., Saito, M. et al. Effects of scrotonin-3 receptor antagonists on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull 2006, 29: 1931-5.